)
Adocia (ADOC) investor relations material
Adocia H2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Achieved positive Phase 3 results for BioChaperone® Lispro in type 1 and type 2 diabetes in China, moving closer to commercialization and triggering a $10m milestone payment.
Launched two new feasibility studies for BioChaperone® with major pharmaceutical partners in diabetes and obesity.
Advanced AdoXLong™ long-acting peptide platform with promising preclinical results and filed a patent application.
Progressed AdoShellⓇ platform with preclinical data and prepared for clinical trial application in Q3 2026.
Secured financing through private placements and a shareholder loan, extending cash runway to early Q2 2027.
Financial highlights
Revenue for 2025 was €1.5m, down from €9.3m in 2024, mainly due to the absence of a major milestone payment recognized in 2024.
Net loss widened to €16.6m in 2025 from €9.3m in 2024, primarily due to lower revenue.
Operating expenses remained stable at €19.6m year-over-year.
Cash position at year-end 2025 was €17.2m, up from €7.5m at end-2024, reflecting milestone receipts and fundraising.
Debt (excluding IFRS16 and derivatives) reduced to €2.0m from €4.5m year-over-year.
Outlook and guidance
Cash runway secured until early Q2 2027, factoring in the new €6m shareholder loan agreement.
Actively seeking new partnerships for mature pipeline assets; potential for additional cash inflow from warrant exercises.
Marketing authorization filing for BioChaperone® Lispro in China is in preparation.
Clinical trial application for AdoShellⓇ platform planned for Q3 2026.
- Strong clinical progress, robust cash, and leadership changes mark a transformative quarter.ADOC
Q4 2025 TU24 Feb 2026 - Strong cash position, positive Phase 3 results, and advancing R&D drive future growth.ADOC
Q3 2025 TU15 Oct 2025 - Net loss of €9.3M in H1 2025, cash runway extended to Q2 2026 after capital raise and milestone.ADOC
H1 202529 Sep 2025 - Cash position strengthened and pipeline progress set stage for key milestones in 2025.ADOC
H1 2025 TU23 Jul 2025 - Innovative peptide delivery platforms advance late-stage diabetes and obesity treatments.ADOC
Investor Presentation27 Jun 2025 - Net loss stable at €8.9M; cash runway to Q3 2025; key diabetes programs advance.ADOC
H1 202413 Jun 2025 - Q3 2024 closed with €9.3M cash, no revenue, and a $10M milestone expected in December.ADOC
Q3 2024 TU13 Jun 2025 - Cash position rises to €13M, pipeline advances, and key partnerships progress amid sector headwinds.ADOC
Q2 2024 TU13 Jun 2025 - Cash runway extended to Q2 2026 as Adocia advances diabetes and obesity programs.ADOC
Q1 2025 TU6 Jun 2025
Next Adocia earnings date
Next Adocia earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Explore our global coverage